ANNAPOLIS, Md., April 27, 2023 /PRNewswire/ — Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, will present for the first time new pediatric data from its Phase 2a clinical trial of a topical candidate for mild-to-moderate atopic…